BMS_PD-L1_onco : Assessment of the PD-L1 Protein as a Biomarker in Oncology and Hematology
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Diffuse Large B-cell Lymphoma|Hodgkin Lymphoma|Metastatic Breastcancer|Non-small Cell Lung Cancer
Sponsor: Rennes University Hospital
Collaborators: Roche Pharma AG|National Research Agency, France